McKee Kelly T. Jr. 4

What Happened
Kelly T. McKee Jr., Chief Medical Officer of GeoVax Labs, was granted a derivative award on 2026-06-17 covering 17,600 shares. The Form 4 lists the acquisition price as $0.00, indicating an option/award grant rather than a cash purchase; reported total value is $0. This is a compensation award (neutral vs. a buy/sell signal).

Key Details

• Transaction date: 2026-06-17; Filing date: 2026-06-22 (appears to be filed after the typical 2-business-day Form 4 window).
• Security type: Derivative (stock option/award) for 17,600 shares; reported price $0.00.
• Vesting: Footnote — the stock option becomes exercisable in three equal annual installments on the first three anniversaries of the grant.
• Shares owned after transaction: Not provided in the supplied filing details.
• No sale or exercise occurred; this is a grant/award (transaction code A).

Context
This filing reports an option/award grant used for executive compensation. No immediate cash transaction or share sale took place, and the options will only become exercisable per the stated vesting schedule. The filing date is later than the transaction date, which reduces near-term transparency for investors.